Stockscreener 앱 받기
20.77
9.20%
1.75
시간 외 거래:
20.98
0.21
+1.01%
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton Pharmaceuticals (NASDAQ:ETON) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
Eton Pharmaceuticals, Inc. (ETON) Q4 Results Fall Short of Projections - Bitget
Eton Pharma 2025 Financial Results & 2026 Outlook | Product Launches Drive GrowthNews and Statistics - IndexBox
ETON: 2025 revenue more than doubled year-over-year, with strong margin gains and robust growth outlook - TradingView
Eton Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Eton Pharma (ETON) Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Eton Pharmaceuticals Q4 2025 beats EPS, stock rises - Investing.com
Eton Pharmaceuticals earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates - Yahoo Finance
ETON PHARMACEUTICALS ($ETON) Releases Q4 2025 Earnings - Quiver Quantitative
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
ETON: 2025 revenues doubled to $80M, but higher costs led to a net loss; growth expected ahead - TradingView
Eton Pharmaceuticals (NASDAQ: ETON) outlines rare-disease drugs, pipeline and IRA pricing risks - Stock Titan
BRIEF-Eton Pharmaceuticals Q4 Net Income USD 1.483 Million - TradingView
After an 83% sales jump, Eton says 2026 revenue will top $110M - Stock Titan
Eton Pharmaceuticals (NASDAQ:ETON) Shares Up 5.8%Time to Buy? - MarketBeat
Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Zenas BioPharma, Inc. (ZBIO) - The Globe and Mail
Aug Outlook: What drives Eton Pharmaceuticals Incs stock priceDividend Hike & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Divisadero Street Capital Management LP Trims Stock Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Cannell Capital LLC Buys 67,230 Shares of Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Why (ETON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6%What's Next? - MarketBeat
Jefferies Financial Group Inc. Invests $1.92 Million in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals (ETON) Expected to Announce Earnings on Thursday - MarketBeat
ETON Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Chipmakers Recap: Is Eton Pharmaceuticals Inc still a buy after recent gainsWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Will Eton Pharmaceuticals Inc. stock deliver strong dividend growth2026 Rallies & Daily Volume Surge Signals - Naître et grandir
Retail Surge: Can Eton Pharmaceuticals Inc lead its sector in growth2025 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
HC Wainwright Analysts Boost Earnings Estimates for ETON - MarketBeat
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), Eton Pharmaceuticals (ETON) and Intellia Therapeutics (NTLA) - The Globe and Mail
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug - Investing.com Australia
Eton Gains on Acquiring Right to Baby Medicine - Baystreet.ca
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Eton Pharmaceuticals Secures U.S. Rights to HEMANGEOL® for Infantile Hemangioma Treatment, Launching May 1st - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - The Manila Times
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals, Inc. has signed a licensing agreement to successfully acquire the exclusive U.S. marketing rights for Hemangeol oral solution from Pierre Fabre Medicament Sas. - Bitget
Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON) and Atai Beckley N.V. (ATAI) - The Globe and Mail
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
2.02%
0.77%
자본화:
|
볼륨(24시간):